[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@SuyogCancer Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1135941148378247168.png) @SuyogCancer Dr Amol Akhade

Dr Amol Akhade posts on X about matterhorn, $8750t, $4568t, $6417t the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1135941148378247168/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1135941148378247168/c:line/m:interactions.svg)

- X Week XXXXXX +108%
- X Month XXXXXX +369%
- X Months XXXXXXX -XX%
- X Year XXXXXXXXX +67%

### Mentions: X [#](/creator/twitter::1135941148378247168/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1135941148378247168/c:line/m:posts_active.svg)

- X Week XX +155%
- X Month XX +417%
- X Months XX +36%
- X Year XXX +50%

### Followers: XXXXX [#](/creator/twitter::1135941148378247168/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1135941148378247168/c:line/m:followers.svg)

- X Week XXXXX +1.50%
- X Month XXXXX +2.80%
- X Months XXXXX +24%
- X Year XXXXX +90%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1135941148378247168/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1135941148378247168/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1135941148378247168/influence)
---

**Social category influence**
[travel destinations](/list/travel-destinations)  XXXX% [stocks](/list/stocks)  XXXX% [currencies](/list/currencies)  XXXX%

**Social topic influence**
[matterhorn](/topic/matterhorn) #70, [$8750t](/topic/$8750t) 3.57%, [$4568t](/topic/$4568t) 3.57%, [$6417t](/topic/$6417t) 3.57%, [pts](/topic/pts) 3.57%, [ct](/topic/ct) XXXX%

**Top accounts mentioned or mentioned by**
[@myesmo](/creator/undefined) [@oncoalert](/creator/undefined) [@dryakupergun](/creator/undefined) [@onclive](/creator/undefined) [@larvol](/creator/undefined) [@erikahamilton9](/creator/undefined) [@oncbrothers](/creator/undefined) [@rmanochakian](/creator/undefined) [@alfdoc2](/creator/undefined) [@dr_elvinaa](/creator/undefined) [@ermanakkus](/creator/undefined) [@gimedonc](/creator/undefined) [@aparna1024](/creator/undefined) [@myriamchalabi](/creator/undefined) [@tompowles1](/creator/undefined) [@drchoueiri](/creator/undefined) [@elmayermd](/creator/undefined) [@drsarahsam](/creator/undefined) [@stephenvliu](/creator/undefined) [@balazshalmosmd](/creator/undefined)
### Top Social Posts [#](/creator/twitter::1135941148378247168/posts)
---
Top posts by engagements in the last XX hours

"🚨 #ESMO25 LBA81 MATTERHORN 🧬 Durvalumab + FLOT vs Placebo + FLOT in resectable gastric / GEJ adenocarcinoma 💥 Final OS positive first peri-operative gastric study showing OS gain with IO + FLOT 🧾 Key results: OS HR XXXX (95% CI 0.630.96 p = 0.021) ✅ Benefit consistent across PD-L1 but CIs X in some subgroups TAP X % HR XXXX (0.411.50) NS TAP X % HR XXXX (0.630.99) ✅ borderline Pathologic responses: pCR XXXX (0.080.96) ✅ MPR XXXX (0.150.68) ✅ Any pR XXXX (0.460.79) ✅ ypN XXXX (0.461.18) NS ypN+ XXXX (0.581.02) NS ypN downstaging: XXXX % vs XXXX % (OR 1.72) 📊 Takeaway: ✅ Significant OS &"  
[X Link](https://x.com/SuyogCancer/status/1978960920396411391) [@SuyogCancer](/creator/x/SuyogCancer) 2025-10-16T23:07Z 8286 followers, 11.7K engagements


"Matterhorn Final OS CURVES. Look at CI for PDL1 less than X %. I will prefer to use it in PDL1 positive pts . What about you For all comers @dr_yakupergun @Erman_Akkus @GIMedOnc @aparna1024 @myESMO @OncoAlert #esmo2025 @MyriamChalabi"  
[X Link](https://x.com/SuyogCancer/status/1979158359711584594) [@SuyogCancer](/creator/x/SuyogCancer) 2025-10-17T12:11Z 8289 followers, 5131 engagements


"🚨 Breaking: Datopotamab-Deruxtecan (DATROWAY) from Daiichi Sankyo & AstraZeneca meets both co-primary endpoints OS + PFS in 1L metastatic TNBC (IO-ineligible). ➡ First ADC ever to show a clinically meaningful OS benefit vs chemo in this setting. Meanwhile Sacituzumab Govitecan (Trodelvy) in ASCENT-03 showed PFS benefit but no OS detriment - Does that mean No OS  full data for both awaited at #ESMO25. We now have X TOPO-I ADCs shaping the mTNBC landscape: X Sacituzumab Govitecan (TROP2 SN-38) X Datopotamab Deruxtecan (TROP2 DXd) X Sac-TMT (TROP2 TMT payload approved) X Trastuzumab Deruxtecan"  
[X Link](https://x.com/SuyogCancer/status/1975395974798582046) [@SuyogCancer](/creator/x/SuyogCancer) 2025-10-07T03:01Z 8282 followers, 5895 engagements


"🩷 POSITIVE trial (ESMO 2025 LBA12) 5-year follow-up confirms its safe to pause endocrine therapy for pregnancy in young HR+ early breast cancer survivors. 👩🍼 Key findings: XXX women median f/u XX mo 5-yr BCFI: XXXX% vs XXXX% (SOFT/TEXT) 5-yr DRFI: XXX% vs XXX% XX% conceived XX% had X live birth (440 babies) XX% resumed ET after X yrs disease-free 💡Takeaway: Temporary ET interruption for pregnancy higher recurrence risk at X yrs. Safe feasible & empowering. #ESMO25 @myESMO @OncoAlert"  
[X Link](https://x.com/SuyogCancer/status/1978953051470991711) [@SuyogCancer](/creator/x/SuyogCancer) 2025-10-16T22:35Z 8284 followers, 8124 engagements


"🧠 ESMO 2025 #LBA92 #ARASAFE Triplet therapy in mHSPC redefined 💊 ADT + Darolutamide + Docetaxel D75 = XX mg/m Q3W (ARASENS) D50 = XX mg/m Q2W 📊 Results Grade 3-5 AEs: XXXX% vs XXXX% (p = 0.0024) NAER (G3/4 neutropenia / death): XXXX% vs XXXX% (p 0.00001) PSA XXX ng/mL: XXXX% vs XXXX% 🩺 Same control less toxicity. ARASAFE shows bi-weekly XX mg/m Docetaxel + Darolutamide may become the new safer triplet standard in mHSPC #ESMO25 @OncoAlert @myESMO"  
[X Link](https://x.com/SuyogCancer/status/1978967185910591632) [@SuyogCancer](/creator/x/SuyogCancer) 2025-10-16T23:31Z 8291 followers, 2411 engagements


"🚨 #ESMO2025 Zongertinib in HER2-mutant NSCLC (1L) ORR XX% DCR XX% Median time to response: XXX mo 6-mo DoR XX% 6-mo PFS XX% Responses rapid deep & across mutation types 💬 Promising early data Zongertinib may redefine first-line therapy for HER2-mutant NSCLC. #ESMO25 @OncLive @myESMO"  
[X Link](https://x.com/SuyogCancer/status/1979225664550244840) [@SuyogCancer](/creator/x/SuyogCancer) 2025-10-17T16:39Z 8281 followers, 1251 engagements


"🚨 LBA2 KEYNOTE-905 (ESMO 2025) Peri-operative Enfortumab Vedotin + Pembrolizumab sets a new standard for cisplatin-ineligible MIBC 💥 🧪 EV + Pembro before & after RC vs RC alone 👥 XXX vs XXX pts FU XXXX mo 📈 Results: EFS HR XXXX (NR vs XXXX mo) OS HR XXXX (NR vs XXXX mo) pCR XX% vs X% 💪 🩹 Grade X AEs XX% vs XX% (mainly skin tox) 💬 Conclusion: EV + Pembro significantly improves EFS OS & pCR with manageable toxicity first effective peri-op regimen for cisplatin-ineligible MIBC. #ESMO25 @myESMO @tompowles1 @DrChoueiri"  
[X Link](https://x.com/SuyogCancer/status/1979322535486660693) [@SuyogCancer](/creator/x/SuyogCancer) 2025-10-17T23:04Z 8286 followers, 1834 engagements


"Destiny breast XX trial . Will this become SOC Let's wait for EFS data to mature @drsarahsam @ErikaHamilton9 @dr_yakupergun @myESMO @OncoAlert #ESMO25"  
[X Link](https://x.com/SuyogCancer/status/1979559530511180168) [@SuyogCancer](/creator/x/SuyogCancer) 2025-10-18T14:45Z 8284 followers, 1844 engagements


"🚨 #ESMO25 ASCENT-03 (LBA20) 🧬 Sacituzumab Govitecan (SG) vs physicians-choice chemo in 1L PD-L1-negative or IO-ineligible mTNBC Results (n = 558; median FU XXXX mo): Median PFS: XXX mo vs XXX mo HR XXXX (0.50-0.78) p XXXXXX ✅ ORR: XXXX % vs XXXX % Median DOR: XXXX mo vs XXX mo OS: immature Safety: G3+ AEs XX % vs XX % Neutropenia XX % / XX % diarrhea X % anemia XX % Tx discontinuation X % vs XX % better tolerability 📈 Interpretation: SG delivers a clinically meaningful PFS gain (3 mo) and more durable responses with manageable toxicity. 💡 Context: Comparable PFS to KEYNOTE-355 (IO + chemo"  
[X Link](https://x.com/SuyogCancer/status/1979704815447134530) [@SuyogCancer](/creator/x/SuyogCancer) 2025-10-19T00:23Z 8293 followers, 4539 engagements


"It is historically difficult to get OS for IO plus VEGF inhibitors plus chemo . Will harmony X get OS MILLIONS Dollars 💸 question @Alfdoc2 @dr_yakupergun @RManochakian @StephenVLiu @BalazsHalmosMD @OncoAlert"  
[X Link](https://x.com/SuyogCancer/status/1979923673403265149) [@SuyogCancer](/creator/x/SuyogCancer) 2025-10-19T14:52Z 8289 followers, 2091 engagements


"Ct DNA in CRC falters again . 🚨 LBA9 DYNAMIC-III 🧬 ctDNA-guided adjuvant de-escalation in stage III colon cancer Phase II/III XXX pts XXX ctDNA; randomized to ctDNA-guided vs standard ACT De-escalation cut oxaliplatin use XXXX% vs XXXX% (p0.001) 3-yr RFS: XXXX% vs XXXX%  XXX% (97.5% CI 8.0%) ❌ NI not met Grade X AEs (6.2% vs 10.6%) hospitalizations (8.5% vs 13.2%) Low-risk (T13N1): RFS XXXX% vs XXXX% ✅ likely safe Critical view: Primary NI failed cannot skip chemo broadly on ctDNA alone False negatives possible with single XX wk test Clinical risk still matters: de-escalate only in low-risk"  
[X Link](https://x.com/SuyogCancer/status/1980078705797120082) [@SuyogCancer](/creator/x/SuyogCancer) 2025-10-20T01:08Z 8292 followers, 1843 engagements


"Congratulations 👏 . ✨ Dr. Sudeep Gupta and team @TataMemorial deliver the first phase III trial showing OS benefit with carboplatin in TNBC (JCO 2025 n=717). Overall (ITT population): 📈 5-yr EFS: XXXX% vs XXXX% (HR XXXX p = 0.081) 💫 5-yr OS: XXXX% vs XXXX% (HR XXXX p = 0.029) pCR: XXXX% vs XXXX% (p 0.001) Premenopausal subgroup: 🚀 5-yr EFS: XXXX% vs XXXX% (HR XXXX p = 0.003) 🏆 5-yr OS: XXXX% vs XXXX% (HR XXXX p = 0.002) In postmenopausal TNBC carboplatin offered no additional EFS or OS benefit underscoring the need for biology-driven rather than intensity-driven approaches in this group."  
[X Link](https://x.com/SuyogCancer/status/1980502221503520847) [@SuyogCancer](/creator/x/SuyogCancer) 2025-10-21T05:11Z 8293 followers, 7933 engagements